Going with the flow: JAK-STAT signaling in JMML.
Knowledge of the distinctive cellular and genetic traits of a cancer aids in diagnosis, prognosis, and potentially treatment. In this issue of Cancer Cell, Kotecha et al. (2008) demonstrate using a sophisticated flow cytometry approach that signal transduction responses to exogenous stimulation can inform diagnosis and pathobiology of myeloproliferative neoplasms.
Kalaitzidis
Demetrios
D
Division of Hematology, Department of Medicine, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. dkalaitzidis@partners.org
Gilliland
D Gary
DG
D014408:Biomarkers, Tumor / Q000378:metabolism*; D049109:Cell Proliferation; D002648:Child; D018450:Disease Progression; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D053614:Janus Kinase 2 / Q000378:metabolism; D054429:Leukemia, Myelomonocytic, Juvenile / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D010766:Phosphorylation; D050799:STAT5 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D050799:STAT5 Transcription Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C507924:JAK2 protein, human; D053614:Janus Kinase 2